These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 34867818)

  • 21. Targeting the tumour microenvironment in platinum-resistant ovarian cancer.
    Cummings M; Freer C; Orsi NM
    Semin Cancer Biol; 2021 Dec; 77():3-28. PubMed ID: 33607246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
    Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
    BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
    Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
    Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy.
    Benard E; Casey NP; Inderberg EM; Wälchli S
    Scand J Immunol; 2020 Oct; 92(4):e12917. PubMed ID: 32557659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance.
    Motohara T; Yoshida GJ; Katabuchi H
    Semin Cancer Biol; 2021 Dec; 77():182-193. PubMed ID: 33812986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunology of tissue homeostasis, ovarian cancer growth and regression, and long lasting cancer immune prophylaxis - review of literature.
    Bukovsky A
    Histol Histopathol; 2021 Jan; 36(1):31-46. PubMed ID: 32896865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities.
    Garlisi B; Lauks S; Aitken C; Ogilvie LM; Lockington C; Petrik D; Eichhorn JS; Petrik J
    Curr Oncol; 2024 Jul; 31(7):3826-3844. PubMed ID: 39057155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Selected mechanisms inducing resistance to immunotherapy in patients with ovarian cancer].
    Pietrzyk N; Piętak P; Pawłowska A; Suszczyk D; Chudzik A; Kotarski J; Wertel I
    Wiad Lek; 2019; 72(7):1397-1402. PubMed ID: 31398175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunology and ovarian cancers.
    Lee WL; Wang PH
    J Chin Med Assoc; 2020 May; 83(5):425-432. PubMed ID: 32149893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-Omics Profiling Identifies Risk Hypoxia-Related Signatures for Ovarian Cancer Prognosis.
    Chen X; Lan H; He D; Xu R; Zhang Y; Cheng Y; Chen H; Xiao S; Cao K
    Front Immunol; 2021; 12():645839. PubMed ID: 34349753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.
    Terlikowska KM; Dobrzycka B; Terlikowski SJ
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
    Lheureux S; Braunstein M; Oza AM
    CA Cancer J Clin; 2019 Jul; 69(4):280-304. PubMed ID: 31099893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy.
    Rajtak A; Ostrowska-Leśko M; Żak K; Tarkowski R; Kotarski J; Okła K
    Front Immunol; 2022; 13():1018256. PubMed ID: 36439144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian Cancer Immunotherapy: Turning up the Heat.
    Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy in rare ovarian cancer.
    Laga T; Vergote I; Van Nieuwenhuysen E
    Curr Opin Oncol; 2021 Sep; 33(5):447-456. PubMed ID: 34230441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy.
    Abou Khouzam R; Goutham HV; Zaarour RF; Chamseddine AN; Francis A; Buart S; Terry S; Chouaib S
    Semin Cancer Biol; 2020 Oct; 65():140-154. PubMed ID: 31927131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
    Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
    J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study.
    Gao Y; Chen L; Cai G; Xiong X; Wu Y; Ma D; Li SC; Gao Q
    Oncoimmunology; 2020; 9(1):1760067. PubMed ID: 32391193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value.
    Liu J; Tan Z; He J; Jin T; Han Y; Hu L; Song J; Huang S
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33043974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
    Khairallah AS; Genestie C; Auguste A; Leary A
    Int J Cancer; 2018 Jul; 143(1):8-15. PubMed ID: 29218796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.